Stereotaxis Reports Second Quarter 2024 Financial Results

ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2024.

“We made significant progress this past quarter on strategic innovation efforts that provide a solid foundation for building a substantial and successful business,” said David Fischel, Chairman and CEO. “Key milestones achieved include successfully obtaining CE Mark in Europe and filing a 510(k) application in the U.S. for GenesisX, significant progress with regulatory reviews of MAGiC in Europe and the U.S., and closing the acquisition of Access Point Technologies (APT).” In a separate press release issued concurrently with this one, Stereotaxis introduced its next-generation robotic system, GenesisX.